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Next-generation sequencing has led to many complex-trait rare-variant (RV) association studies. Although single-variant association
analysis can be performed, it is grossly underpowered. Therefore, researchers have developed many RV association tests that aggregate
multiple variant sites across a genetic region (e.g., gene), and test for the association between the trait and the aggregated genotype. After
these aggregate tests detect an association, it is only possible to estimate the average genetic effect for a group of RVs. As a result of the
"winner’s curse," such an estimate can be biased. Although for common variants one can obtain unbiased estimates of genetic parameters
by analyzing a replication sample, for RVs it is desirable to obtain unbiased genetic estimates for the study where the association is iden-
tified. This is because there can be substantial heterogeneity of RV sites and frequencies even among closely related populations. In order
to obtain an unbiased estimate for aggregated RV analysis, we developed bootstrap-sample-split algorithms to reduce the bias of the
winner’s curse. The unbiased estimates are greatly important for understanding the population-specific contribution of RVs to the heri-
tability of complex traits. We also demonstrate both theoretically and via simulations that for aggregate RV analysis the genetic variance
for a gene or region will always be underestimated, sometimes substantially, because of the presence of noncausal variants or because of
the presence of causal variants with effects of differentmagnitudes or directions. Therefore, even if RVs play a major role in the complex-
trait etiologies, a portion of the heritability will remainmissing, and the contribution of RVs to the complex-trait etiologies will be under-
estimated.Introduction
Nearly a decade of genome-wide association studies
(GWASs) has led to the identification of many complex-
trait associations with common variants (minor allele
frequency [MAF] > 5%).1 The genetic-effect sizes of these
common variants are for the most part very modest.
Even for diseases with a strong genetic component, the
identified common variants usually only explain a small
portion of the total genetic heritability. For example, in
a recent GWAS of human height, >100 significant single
nucleotide polymorphism (SNP) markers were identified,
but these collectively explained only ~10% of the herita-
bility.1 In a study of Crohn disease, >30 loci were identi-
fied, but they explain <10% of the overall heritability.2,3
For GWASs, indirect mapping is performed, and therefore
the proportion of heritability a particular causal variant
contributes can be underestimated as a result of the incom-
plete linkage disequilibrium (LD) between the markers and
the causal variant. Although genotyping larger sample
sizes might elucidate additional loci for common variants
with smaller effect sizes, it is clear that a major portion of
the missing heritability remains unexplained.
Multiple hypotheses on missing heritability have been
proposed. For example, it was suggested that the unex-
plained portion of genetic variance can be due to gene 3
gene interactions, gene3 environment interactions, struc-
tural variation, epigenetics, and rare variants.4 In partic-1Department of Molecular and HumanGenetics, Baylor College of Medicine, H
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The Americular, researchers are vigorously investigating the "common
disease, rare variant" (CD/RV) hypothesis to determine
whether rare variants (withMAF% 1%) and low-frequency
variants (with MAF between 1% and 5%) explain a large
portion of the missing heritability.5,6 There is solid evi-
dence supporting the CD/RV hypothesis, which proposes
that low-frequency and rare variants are involved in the
etiology of complex traits.6,7 Indirect association mapping
approaches used in GWASs are underpowered to detect
associations with rare variants because of the low LD (r2)
between common tagSNPs and rare causative variants.8
Therefore, it is likely that many rare causative variants
remain undetected even after extensive GWAS efforts.
With the implementation of next-generation sequencing
technology, large-scale sequence-based studies have been
made possible. The validity of the CD/RV hypothesis and
the proportion of missing heritability that is attributable
to rare variants can now be examined.
For association mapping of rare variants, it is neither
powerful nor numerically stable to analyze each variant
individually. Gene-based tests, in which multiple rare vari-
ants in a gene region are jointly analyzed so that signals are
aggregated and the number of tests is reduced, are usually
performed. Many statistical tests have been proposed for
detecting binary or quantitative-trait (QT) associations.
Such tests include the combined multivariate and col-
lapsing test (CMC),8 gene- or region-based analysis of vari-
ants of intermediate and low frequency test (GRANVIL),9ouston, TX 77030, USA; 2Department of Statistics, Rice University, Houston,
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weighted sum statistic test (WSS),10 the variable threshold
test (VT),11 the kernel-based adaptive cluster test (KBAC),12
the data adaptive sum test,13 the RARECOVER method,14
C-alpha test,15 the sequence kernel association test
(SKAT),16 and the replication-based test (RBT), among
others.17 Among the rare-variant association methods,
the combined multivariate and collapsing method,
GRANVIL, WSS, KBAC, and RBT are based upon analyzing
selected variants according to functional annotations or
fixed cutoffs for the MAF. Variants at different nucleotide
sites are weighted and aggregated. The multi-site genotype
for the gene locus is coded as a single variable and tested
for associations with the QT of interest. For these tests,
applying different weighting schemes can increase power,
in that the variants that are more likely to be causal can
be assigned larger weights than the variants that are less
likely to be causal. RARECOVER and VT are variable
selection based methods. In addition to testing for
associations with the QT of interest, RARECOVER and
VT can also select the set of variants where the association
statistics are maximized. C-alpha and SKAT differ from
other methods in that they are based on the random-
effects model. They assume a common distribution for
the phenotypic effects of variants at different sites and
test for the null hypothesis that the distribution has zero
variation.
After a significant association is identified, the associa-
tion signal needs to be interpreted, and relevant genetic
parameters should be estimated. In particular, it is of
interest to estimate the genetic variance explained by
the variants that are jointly analyzed. When variable-
selection-based methods are used, it is necessary to esti-
mate the genetic variance explained by the set of selected
variants that maximize the association test statistics (e.g.,
Z score statistics). The estimated genetic parameters are
important for interpreting the association signal, quanti-
fying the amount of heritability a specific gene contributes
to the trait, making risk predictions, and designing replica-
tion studies.18
Most of the gene- and region-based rare-variant-
association methods focus on testing the null hypothesis
of no gene-QT associations, but they cannot be applied
to estimating genetic parameters. For the rare-variant asso-
ciation tests that are based upon weighting or collapsing
variants, if the weights are only dependent on the multi-
site genotype, average genetic effects (AGEs), defined by
the change in the QT per unit of change in the locus-
specific genotype coding, can be estimated. Variable selec-
tion-based methods, e.g., VT and RARECOVER, calculate
either CMC or GRANVIL statistics for different groups of
rare variants and use their maximum as the test statistic.
Therefore, after an association is detected, genetic effects
can be estimated for the subset of variants where the
CMC or GRANVIL statistics are maximized.
We prove theoretically that the AGEs for a group of rare
variants can be efficiently estimated. The maximum-likeli-
hood estimates or least-square estimates of AGEs obtained586 The American Journal of Human Genetics 91, 585–596, Octoberfrom an independent sample are consistent even if there
are noncausal variants and/or if there are causal variants
with heterogeneous effects in the gene region. We demon-
strate theoretically that when multiple rare variants are
jointly analyzed, the locus-specific genetic variance will
always be underestimated, unless either all the variants
that are jointly analyzed are causal and have equal effects
or optimal weights can be assigned.
There can be considerable heterogeneity in rare-variant
sites and frequencies even between closely related popula-
tions, e.g., neighboring European populations.19 The
genetic effects of rare variants in these populations can
also be vastly different. It is therefore desirable to estimate
the genetic effect by using the same sample from which
the association is identified. However, a problem in doing
so is that the naive estimates can be seriously inflated as
a result of the winner’s curse.20–25 Additionally, if the
AGE is estimated for the set of variants where the associa-
tion test statistics (e.g., Z score statistics) are maximized,
an even larger bias can be caused by the model selection
procedure. We modified the resampling-based approach
by Sun and Bull25 and proposed appropriate bootstrap-
sampling-split algorithms that can correct for the bias of
AGE estimates. The algorithm is generic and can be applied
to estimating genetic parameters for the associations iden-
tified by any rare-variant test.
The properties of the estimators of AGEs and the
locus-specific genetic variance were investigated. Genetic
data were generated according to a rigorous population-
genetic model as described in Kryukov et al.26 QTs were
simulated with parameters estimated for clinically rele-
vant complex traits.11,27,28 In the simulation experiments,
genetic-effect estimates are shown when association
testing was performed with CMC,8 VT,11 and extended
WSS10,29 tests.
As an application, a published data set from the
Dallas Heart Study was revisited.27,28 Sequence data from
ANGPTL3 (MIM 604774), ANGPTL4 (MIM 605910),
ANGPTL5 (MIM 607666), and ANGPTL6 (MIM 609336)
were tested for associations with nine metabolic QTs. For
each QT, by implementing the CMC, VT, and WSS tests,
we performed association analyses by using the 1,045
European American study subjects. The results coincide
with those of previous studies of complex traits30 and
provide solid support for our simulation experiments.Material and Methods
Genetic Models and Genetic Parameters of Interest
It is assumed that a set of S variant sites are jointly analyzed in the
sample. S can be determined by prespecified frequency thresholds,
functional annotations, etc. The multi-site genotype for indi-
vidual i is given by X
!
i ¼ ðX1i ;X2i ;/;XSi Þ, where Xsi is an indicator
of whether individual i contains rare variants at site s, (e.g.,
Xsi ¼ 1 when the individual is homozygous for the rare allele or
heterozygous at site s). The MAF for variants at site s is denoted
by ps. Hardy-Weinberg equilibrium is assumed in the general5, 2012
population, so the rare-variant carrier frequency at site s satisfies
qs ¼ PðXsi ¼ 1Þ ¼ p2s þ 2psð1 psÞ.
The following general QT model is assumed:
Yi ¼ ~aþ
X
s˛c
~bsX
s
i þ εi (1)
where C4S is the set of causative variants that affect the quantita-
tive phenotype. Rare-variant sites in S, but not in C, are noncausal
and do not influence the QT. The error terms εi are assumed to be
independently and identically distributed, i.e., εi  Nð0; t2Þ. Yi can
be either the QT of interest or the QT residual after an adjustment
for confounders, such as age, sex, and population substructure.
When an association is identified in the stage 1 sample, it is
of interest to estimate the following two parameters for a
certain group G of rare variants: (1) the causative-variant effects,
~bs; s˛GXC and (2) the genetic variance explained by a group of
rare variants G,
s2G ¼ var
 X
s˛GXC
~bsX
s
i

¼
X
s˛GXC

~bs
2
var

Xsi
¼ X
s˛GXC

~bs
2
qs

1 qs

(2)
The proportions of QT variance attributable to causative variants
can be defined by
h2G ¼
s2G
t2 þ s2G
: (3)
If the overall heritability h2 for the QT of interest is known, the
proportion of heritability that is attributable to the identified
group of variants can also be defined, i.e.,
FG ¼ h
2
G
h2
: (4)
In practice, it is not possible to directly estimate ~bs, s
2
G, h
2
G, or
FG because causal and noncausal variants cannot be distin-
guished in real applications. Although in principle one can
obtain unbiased estimates for ~bs by fitting a multiple regression
model using all variants as covariates, it is neither numerically
stable nor statistically efficient to analyze each rare variant
individually.Efficient Maximum-Likelihood Estimators for the
Locus-Specific AGE
Instead of estimating genetic effects for each individual rare
variant, we can estimate the AGE for a group of rare variants.
The following model is usually used in the inferences and estima-
tions of rare-variant genetic effects, i.e.,
Yi ¼ aþ bAGEK

X
!
i;Yi
þ ei; (5)
where the error term is assumed to follow a normal distribu-
tion ei  Nð0; t2Þ under the null hypothesis. The coding
function KðX!i;YiÞ for the multisite genotype is generic and can
incorporate many variant collapsing and grouping schemes.
For instance, in the collapsing method, the coding function
has the form of KðX!i;YiÞ ¼ dð
P
s˛SX
s
i > 0Þ, where variant carriers
are coded as 1 and noncarriers are coded as 0. For the WSS
method that was first described by Madsen and Browning10 and
extended by Lin and Tang,29 the coding function has the form
of KðX!i;YiÞ ¼
P
s˛S bwsXsi , and the weights depend on the multi-
site genotypes. Other types of weights are also possible. The
parameter can be interpreted as the change of the QT per
unit of change in the locus-specific genotype coding, i.e.,The AmericbAGE ¼ vEðYijKðX
!
iÞÞ=vKðX!iÞ. The AGE-based genetic variance
can also be estimated, i.e., s2AGE ¼ b2AGEvarðKðX
!
iÞÞ.
It should be noted that for model (5), ei is only normally distrib-
uted under the null hypothesis of no QT-gene association.
Under the alternative hypothesis, because there are noncausative
variants or because there are causal variants with effects in
different magnitudes or directions, the residual errors may not
always follow a normal distribution. However, as we showed in
the supplemental methods, when the CMC coding is used, the
model in formula (5) is still approximately correct. The locus
AGE estimates obtained in an independent sample are asymptoti-
cally efficient and satisfy
bbCMCAGE/a:s: bCMCAGE ¼
P
s˛GXC
~bsqsP
s˛G
qs
: (6)
When weighted sum coding is used and the weights depend on
the multisite genotypes, it is difficult to specify the joint-likeli-
hood model of genotype and phenotypes. Instead, if a random
population sample is collected, least-square estimates, which
require less stringent distributional assumptions, can be obtained.
In this case, as we show in the Supplemental Data available
online, bbWSSAGE/a:s bWSSAGE ¼PswscovðXsi ;YiÞ=PsðwsÞ2varðXsi Þ, where
bws/a:s: ws.
Because of noncausal variants or causal variants with effects of
different magnitudes and directions, as well as the weights that
are assigned to each variant site, the AGEs might be different in
value from the causal variant effects, i.e., ~bs; s˛C. However, the
locus-specific genetic variance estimated from model (5) is always
no greater than the true genetic variance, i.e., s2G%s
2
AGE. Therefore,
when multiple variants are jointly analyzed, the locus-specific
genetic variance will be underestimated, and the estimates should
be interpreted as a lower bound for the true locus-specific genetic
variance.
Correcting for the Bias Due to the Winner’s Curse
Most of the current sequence-based genetic studies can be under-
powered because of the size of the data sets and the moderate
effect sizes of variants involved in complex-trait etiologies. There-
fore, the bias of the naive estimator can be substantial as a result of
the winner’s curse. Many methods have been developed to reduce
the bias due to the winner’s curse for single-marker tests in associ-
ation studies of common variants; such tests include the likeli-
hood-based methods by Xiao and Boehnke23,24 and by Zo¨llner
and Pritchard,22 the resampling-based method by Sun and
Bull,25 and the Bayesian method by Xu et al.31 Both the likeli-
hood-based and Bayesian methods require evaluating power func-
tions under the alternative hypothesis. However, this is impossible
for rare-variant association studies because (1) p values for most
rare-variant tests have to be obtained empirically via permuta-
tions, so there are no analytic formulas for calculating power
and (2) the power for a rare-variant test depends on high-dimen-
sional parameters, which include variant-site frequency spectrums
and the phenotypic effects for different causal variant sites.
Evaluating power functions on a fine grid in high-dimensional-
parameter space is computationally intractable.
The resampling-based methods have desirable properties, in
that they are nonparametric and do not require that power be
calculated for a rare-variant test under the alternative hypothesis.
However, the method by Sun and Bull25 is not directly applicable
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association analysis. This is for two reasons. First, in Sun and
Bull,25 the standardized genetic-effect estimates are used as the
test statistic, i.e., Tbb ¼ bb=seðbbÞ. In rare variant analysis, a different
test statistic, T, may be used for detecting associations. The correc-
tion procedure for the winner’s curse can be complicated by the
requirement that both Tand Tbb be statistically significant. Second,
for some variable-selection-based tests, the set of variants that
maximize the association test statistics are selected, and AGE
parameters are estimated for this selected subset of variants. The
bias of the estimates can be affected by both the winner’s curse
and the variable selection procedure.
To overcome these problems specific to rare-variant association
testing, we developed two different bootstrap-sample-split algo-
rithms. If the associationwas identified by a test that analyzes vari-
ants determined by some pre-specified criteria (e.g., fixed MAF
cutoffs or functional annotations), genetic parameters for the
set of variants that are jointly analyzed can be estimated via
algorithm I. If the association is identified by a variable-selec-
tion-based method, such as VT or RARECOVER, genetic parame-
ters for the set of selected variants that maximize the test statistics
can be estimated via algorithm II.
In the BSS algorithm, for each bootstrap the original data set is
split into a bootstrap sample and a residual sample, which are
mutually exclusive. Hypothesis testing is performed with the
bootstrap sample. If the statistic is significant, AGEs are estimated
for both the bootstrap and the residual samples. When the two
estimates are compared, the bias that is due to winner’s curse
and variable selection procedure can be quantified. So that stable
estimates of the biases are obtained, the bootstrapping procedure
is repeated multiple times. Deducting the bias from the naive
estimates gives the BSS-corrected estimates. Technical details for
the two algorithms can be found in the Supplemental Data.Simulation of Genetic and QT Data and Association
Analyses
Genetic data were generated according to Kryukov et al.26 A
conventional four-parameter model was used for describing the
demographic history of the European population.32 Purifying
selection was also modeled for new nonsynonymous muta-
tions. Details on this population-genetic model can be found in
Kryukov et al.26
QT were simulated according to model (1). Different propor-
tions of nucleotide sites were randomly chosen to be causative
(i.e., 10%, 50%, and 90%), which covers a broad class of scenarios.
The magnitudes of the genetic effects of causal variants are
assumed to be inversely correlated with the MAFs, i.e,
j ~bs j ¼
~bmax 

~bmax  ~bmin


maxs˛C

ps
mins˛Cps3

ps min

ps

; s˛C
A special case is when the magnitudes of the effects of the causal
variants are equal, i.e., ~bmin ¼ ~bmax. We considered scenarios
where (1) ~bmin ¼ ~bmax ¼ 0:25, (2) ~bmin ¼ ~bmax ¼ 0:5, and (3)
~bmin ¼ 0:125; ~bmax ¼ 0:75. Under each set of values of ~bmin and
~bmax, we considered scenarios where (1) all effects of causal vari-
ants are unidirectional and (2) 80% of causal variants increase
the mean QT value and the remaining 20% of causal variants
decrease mean QT value.
Data sets were simulated for random-population-based studies.
For each replicate, genetic data and QTs for 20,000 individuals
were generated. For a medium-sized study, 3,000 individuals
were randomly chosen from the pool and analyzed in stage 1588 The American Journal of Human Genetics 91, 585–596, October(initial study) by the CMC, WSS, and VT methods. The statistical
significance was evaluated for a ¼ 0:05. For a large-scale whole-
exome study, 10,000 individuals were randomly sampled and
analyzed in stage 1 by the CMC method. For this example, an
exome-wide significance level of a ¼ 2:53106 is used.
If the association test statistic was significant in stage 1, a stage 2
(replication) sample of equivalent size was selected from the
remaining individuals in the pool. For the rare-variant association
analyses implementing CMC and WSS, variants with MAF % 1%
were analyzed. For VT, Z score statistics with CMC coding are
computed for each frequency threshold, and their maximum is
used as the test statistic. Because we were interested in detecting
associations with rare variants and because common variants
can be individually tested for associations, we only analyzed vari-
ants with MAF % 5%. This is slightly different from the original
version of VT in Price et al.,11 whose analysis included all variants
in the gene region. Permutation was used to obtain the p value
empirically for WSS and VT. For each scenario, we generated
30,000 replicates to obtain a sufficient number of significant repli-
cates even for studies with low power.
Analysis of Sequence Data Set of ANGPTL3, ANGPTL4,
ANGPTL5, and ANGPTL6
The sequence data set for ANGPTL3, ANGPTL4, ANGPTL5, and
ANGPTL6 was generated by the Dallas Heart Study (DHS). The
DHS sample was collected from Dallas County residents whose
lipids and glucose metabolism had been characterized and
recorded.33,34 For the four genes that were sequenced, a total of
348 nucleotide sites of sequence variations were uncovered.
Most of the uncovered variants were rare, and 86% of them had
MAFs % 1%.27 Nine phenotypes were measured and tested for
their associations with rare genetic variants, i.e., body mass index
(BMI), diastolic blood pressure (DiasBP), systolic blood pressure
(SysBP), total cholesterol level (TCL), low-density lipoprotein
(LDL), high-density lipoprotein (HDL), triglyceride (TG), very-
low-density lipoprotein (VLDL), and glucose (Gluc).
Association analyses were carried out with European-American
samples. The CMC, WSS, and VT tests were used for analysis of
the data set. The CMC and WSS methods were used for analysis
of rare variants with MAF % 3%. For each identified association,
bAGE - and AGE-based genetic variances s
2
AGE are estimated for vari-
ants with MAF % 3%. For the VT test, variants with MAF % 5%
were analyzed, and genetic parameters were estimated for the set
of selected variants that maximize the Z score statistics.11Results
Summary Statistics of Simulated Data Sets
Summary statistics are shown for different simulation
scenarios, which include power, the cumulative causal-
variant frequencies, all variant frequencies, and the
number of variant nucleotide sites observed. Summary
statistics are shown for the cases when rare-variant associ-
ation analysis was performed with the CMC (Table 1), WSS
(Table S1), and VT (Table S2). Because of the small pheno-
typic effects of causal variants and the low aggregated
variant frequencies, the power to detect an association
with a sample of 3,000 individuals is generally insufficient
(e.g., <80%). In many scenarios, the power of VT is higher
than that of theWSS and CMCmethods. Because of a fixed5, 2012
Table 1. Summary Statistics for Analyses Performed with CMC
~bmax ~bmin
Percentage of Causal
Variants Powera
Cumulative Causal-
Variant Frequenciesb
Cumulative Rare-
Variant Frequenciesb bCMCAGE
c
Total Number of Variant
Nucleotide Sites
Causal Variant Effects Are Unidirectional
0.25 0.25 10% 0.058 0.003 0.017 0.035 38.498
0.25 0.25 50% 0.157 0.012 0.019 0.151 38.937
0.25 0.25 90% 0.33 0.019 0.02 0.23 39.222
0.5 0.5 10% 0.083 0.005 0.018 0.107 38.71
0.5 0.5 50% 0.377 0.012 0.019 0.304 39.251
0.5 0.5 90% 0.754 0.016 0.018 0.455 38.964
0.75 0.125 10% 0.091 0.004 0.018 0.128 38.946
0.75 0.125 50% 0.483 0.01 0.018 0.37 39.378
0.75 0.125 90% 0.863 0.015 0.017 0.579 39.192
Causal Variant Effects Are Bidirectionald
0.25 0.25 10% 0.057 0.003 0.017 0.021 38.458
0.25 0.25 50% 0.114 0.012 0.02 0.109 38.891
0.25 0.25 90% 0.203 0.018 0.02 0.173 39.023
0.5 0.5 10% 0.077 0.004 0.019 0.068 38.529
0.5 0.5 50% 0.263 0.012 0.02 0.232 38.925
0.5 0.5 90% 0.495 0.017 0.019 0.342 38.868
0.75 0.125 10% 0.085 0.004 0.018 0.087 38.862
0.75 0.125 50% 0.314 0.011 0.018 0.285 39.186
0.75 0.125 90% 0.572 0.016 0.018 0.426 39.24
Different portions of variants were randomly chosen to be causal, i.e., 10%, 50%, and 90%. Causal-variant effects are assumed to be either unidirectional or
bidirectional. The magnitude of causal-variant effects is assumed to be either constant or inversely correlated with variant MAFs. Only those variants with
MAFs % 1% are analyzed in aggregate across the genetic region. The power, cumulative carrier frequencies of causal and all variants within the region, AGE,
and number of variant nucleotide sites are reported.
aThe power is calculated from 30,000 replicates under a significance level of a ¼ 0:05.
bWe calculated the cumulative causal- and all-variant carrier frequencies within the genetic region by averaging over all replicates with significant test statistics.
cAGE is calculated for variants with MAF % 1% by Equation 5, and reported values of bCMCAGE are averages of the model parameter b
CMC
AGE over the replicates with
significant CMC statistics.
dAmong the causal variants, 80% increase the mean QT value, and the remaining 20% decrease the mean QT value.variant frequency threshold (i.e., MAF% 1%), either causal
variants with higher frequencies can be excluded from the
analysis or more frequent noncausal variants can be
included. The power advantage of VT over CMC can be
large when there is a high portion of noncausal variants
within the analyzed genetic region. For example, when
50% of the causal variants have a constant effect with
~bs ¼ 0:5; s˛C, the power for CMC, WSS, and VT tests are,
respectively, 37.7% (Table 1), 33.5% (Table S1), and
45.4% (Table S2). If 90% of the variants are causal, the
power of VT (79.4%; Table S2) is only slightly higher
than the power of CMC (75.4%; Table 1) or WSS (72.4%;
Table S1). The results are also shown for the simula-
tion study where 10,000 samples are sequenced and an
exome-wide significance level of a ¼ 2:53106 is used
(Table S3). For some scenarios, e.g., when 10% of the vari-
ants are causal and have effect bs ¼ 0:25; s˛C, the power
can be extremely low (0.2%) even when 10,000 samples
are sequenced (Table S3).The AmericIn our comparisons, for each replicate we generated
a different pool of samples by using forward-time simula-
tion. Therefore, the variant MAFs, the set of causal vari-
ants, and the value of the model parameter bAGE can be
different between replicates. It is important to note that
the reported values bCMCAGE , b
WSS
AGE , and b
VT
AGE are averages of
the model parameters bCMCAGE , b
WSS
AGE, and b
VT
AGE over the repli-
cates with significant test statistics. Therefore, they can
also be affected by the power to detect an association.
The power is generally higher if the gene region has a larger
AGE. Therefore, the average AGE that is calculated from
the replicates with significant test statistics will be greater
than when the average is obtained from all replicates. For
example, when ~b ¼ 0:5 and 50% of the variants are causal,
the value of bCMCAGE and b
VT
AGE would be equal to 0.25 if
averaged over all replicates, regardless of whether the test
statistic is significant or not. For the replicates where the
test statistic is significant, the mean proportion of causalan Journal of Human Genetics 91, 585–596, October 5, 2012 589
variants is >50%, and the average of AGEs is given by
bCMCAGE ¼ 0:304 (Table 1) and bVTAGE ¼ 0:353 (Table S2) for
rare-variant association analyses performed with CMC
and VT.
Results are also shown for cases when a gene region
contains causal variants with bidirectional effects—that
is, when 80% of the causal variants increase mean QT
values and the remaining 20% decrease the mean QT
values. It can be observed that the bidirectionality of the
causal-variant effect reduces the power of all tests and
also causes a reduction in the AGE values. For example,
when ~bs ¼ 0:5; s˛C and 90% of the variants are causal, if
the effects of all variants are unidirectional, the powers
for CMC, WSS, and VT are 75.4%, 72.4%, and 79.4%,
respectively, and the values of bCMCAGE , b
WSS
AGE, and b
VT
AGE are
0.455, 0.279, and 0.479, respectively. However, when the
variant effects are bidirectional, the power decreases to
49.5%, 40.7%, and 59.7%, and bCMCAGE , b
WSS
AGE , and b
VT
AGE reduce
to 0.342, 0.189, and 0.357, respectively (Table 1; Tables S1
and S2). Similarly, when 90% of the variants are causal, the
effect sizes of causal variants are variable, ~bmax ¼ 0:75,
~bmin ¼ 0:125, and the effects are unidirectional, the powers
for CMC, WSS, and VT are 86.3%, 88.0%, and 89.4%,
respectively, and the mean values for bCMCAGE , b
WSS
AGE, and
bVTAGE are 0.579, 0.382, and 0.635, respectively. When the
effects of causal variants are bidirectional, the powers for
the three tests decrease to 57.2%, 56.1%, and 68.9%,
respectively, and bCMCAGE , b
WSS
AGE , and b
VT
AGE become 0.426,
0.255, and 0.467, respectively (Table 1; Tables S1 and S2).Estimates for the AGE and Locus-Specific Variance
in Aggregate Rare-Variant Analysis
Biases and variances for different estimators of AGE-based
genetic variances were examined for a broad variety of
models. First, the theoretical properties of AGE-based
genetic-variance estimators were verified via simulation
experiments. Specifically, the AGE-based genetic variance,
s2AGE (i.e., ðsCMCAGE Þ2, ðsWSSAGEÞ2, and ðsVTAGEÞ2 for analyses per-
formed with CMC, WSS, and VT, respectively) is always
no greater than the true genetic variance in all the
scenarios that were examined. The difference between s2G
and s2AGE is larger when there is a higher portion of
noncausal variants or when there is a mixture of causal
variants that have effects in different directions. In our
simulation experiment, the average values of AGE-based
genetic variance [i.e., ðsCMCAGE Þ2, ðsWSSAGEÞ2, and ðsVTAGEÞ2 ] and
true genetic variance (i.e., s2G) were compared for the repli-
cates with significant test statistics. For example, for
the analysis using CMC, if 90% of the variants are causal
and all causal variants have an effect of ~bs ¼ 0:5; s˛C,
the average AGE-based variance is equal to ðsCMCAGE Þ2 ¼
0.3683 102 (Figure 1F). In this case, ðsCMCAGE Þ2 is 8.9% lower590 The American Journal of Human Genetics 91, 585–596, Octoberthan the average true genetic variance, s2G. It should be
noted that an unbiased estimate of the genetic variance
could be obtained if optimal weights were assigned or if
all variants were causal with equal effects. However, if
only 50% of the variants are causal, ðsCMCAGE Þ2 is considerably
reduced, i.e., ðsCMCAGE Þ2 ¼ 0.1963 102, which is 33.1% lower
than the true genetic variance (Figure 1E). When there is
a mixture of variants with effects in different directions,
the discrepancy between AGE-based genetic variance,s2AGE,
and the true genetic variance,s2G, may be increased further.
For example, if 90% of the causal variants have positive
effect 0.5 and the other 20% have a negative effect
of 0.5, the average value of AGE-based genetic variance
is ðsCMCAGE Þ2 ¼ 0.252 3 102, which is 41.3% lower than
the average value for the true locus-specific genetic
variance (Figure 2F). When the genetic effects of causal
variants are variable with MAFs, the locus-specific genetic
variance will also be underestimated. For example, when
bmax ¼ 0:75, bmin ¼ 0:125, and 90% of the variants are
causal and have unidirectional effects, the locus-specific
genetic variance is underestimated by 14.8%. When causal
variants have bidirectional effects, ðsCMCAGE Þ2 is 48.6% lower
than s2G. Similar results are observed when the analysis is
performed with WSS and VT.
It should be noted that ðsCMCAGE Þ2 (Figures 1 and 2) and
ðsWSSAGEÞ2 (Figures S1 and S2) represent the average value of
the genetic variance explained by variants with MAF %
1%. They are not directly comparable to ðsVTAGEÞ2 (Figures
S3 and S4), which equals the average value of the genetic
variance explained by the set of variants where the Z score
statistics are maximized. For example, when 90% of
variants are causal and all causal variants have an effect
of ~b ¼ 0:5, ðsVTAGEÞ2 is 5.0% smaller than s2G (Figure S3F).
There is a much greater reduction in ðsCMCAGE Þ2 (8.9%, Fig-
ure 1F) when variants with MAF % 1% are analyzed. It is
interesting to note that in the same scenario, ðsWSSAGEÞ2 is
49.6% smaller than s2G (Figure S1F). This is because,
when WSS is used, the assigned weights are not optimal,
i.e., noncausal, low-frequency variants are up-weighted,
and higher frequency, causal variants are down-weighted.
WSS can thus underestimate the locus-specific genetic
variance to a greater extent than methods, such as CMC,
that treat each variant interchangeably.
For the estimators obtained from an independent stage 2
sample, i.e., ðbsS2AGEÞ2, the biases are very small in all
scenarios (<0.01 3 102), which verifies the asymptotic
consistency of the estimators ðbsCMC;S2AGE Þ2, ðbsWSS;S2AGE Þ2, and
ðbsVT ;S2AGE Þ2.
However, the biases due to the winner’s curse or variable
selection procedures can be considerable when estimation
is performed with the discovery sample. This is compatible
with the observations from common-variant association5, 2012
Figure 1. Estimates of Genetic Variance When Genetic Association Testing Is Performed with CMC
Data were generated under the assumption that the causal-variant effects are unidirectional. The replicates with significant test statistics
were used for estimating genetic parameters for the variants with MAF% 1%. Mean values and standard deviations are shown for the
naive, BSS-corrected, and independent estimators, mean values are displayed as bar plots, and standard deviations are represented by
error bars. The true genetic variance and AGE-based genetic variance were calculated analytically. The reported values s2G and ðsCMCAGE Þ2
are averages over the replicates with significant test statistics. Examined scenarios included those in which (A) 10% of variants are causal
and ~bmax ¼ ~bmin ¼ 0:25, (B) 50% of variants are causal and ~bmax ¼ ~bmin ¼ 0:25, (C) 90% of variants are causal and ~bmax ¼ ~bmin ¼ 0:25, (D)
10% of variants are causal and ~bmax ¼ ~bmin ¼ 0:5, (E) 50% of variants are causal and ~bmax ¼ ~bmin ¼ 0:5, (F) 90% of variants are causal and
~bmax ¼ ~bmin ¼ 0:5, (G) 10% of variants are causal, ~bmax ¼ 0:75, and ~bmax ¼ 0:125, (H) 50% of variants are causal, ~bmax ¼ 0:75, and
~bmax ¼ 0:125, and (I) 90% of variants are causal, ~bmax ¼ 0:75, and ~bmax ¼ 0:125.analyses.21,22,25 For example, if 50% of the variants are
causal, and the causal-variant effect is ~bs ¼ 0:5; s˛C, the
power of the CMC test is 37.7%. The average bias for the
naive estimator ðbsCMC;naiveAGE Þ2  ðsCMCAGE Þ2 is 0.133 3 102,
which is 67.8% of the average true parameter value (i.e.,
ðsCMCAGE Þ2 ¼ 0:1963102) (Figure 1E). As a result of both
the variable selection procedure and the winner’s curse,
the biases for the naive estimator can also be large when
ðbsVT ;naiveAGE Þ2 is estimated for the group of variants where
the Z score statistics are maximized. For instance, when
analysis is performed with VT (Figure 2B) under the same
scenario, the average bias ðbsVT ;naiveAGE Þ2  ðsVTAGEÞ2 is 0.153 3
102, which is 35.6% more than the average true value
ððsVTAGEÞ2 ¼ 0:4293102Þ.
Finally, we examined the performances of BSS algo-
rithms and showed that the biases can be consistentlyThe Americreduced. The biases of BSS-corrected estimators are compa-
rable to those of independent estimators inmost scenarios.
For example, under the model where the causal-variant
genetic effects are inversely correlated with MAFs with
~bmax ¼ 0:75 and ~bmin ¼ 0:125, if 10% of the variants are
causal, the power for VT is 12.1%. The average biases for
the BSS-corrected estimator ðbsVT ;BSSAGE Þ2 is 0:0163102,
whereas the biases for the naive estimator and indepen-
dent estimator are 0.211 3 102 and 0.011 3 102, respec-
tively. In certain scenarios where the power is higher, there
can be some over-corrections for the BSS estimators. Exam-
ples include the scenario where ~bmax ¼ 0:75, ~bmax ¼ 0:125,
and 90% of the variants are causal. In this case, the power
for VT is 89.4%, and the average value of the estimate
ðbsVT ;BSSAGE Þ2 is deflated by 0.049 3 102 (Figure 1I). The
performance for the BSS estimator is similar when analysis
is performed by the VT or WSS method.an Journal of Human Genetics 91, 585–596, October 5, 2012 591
Figure 2. Estimates of Genetic Variance When Genetic Association Testing Is Performed with CMC
Data were generated under the assumption that the causal-variant effects were bidirectional. It is assumed that 80% of the causal variants
increase themean QT value, whereas the remaining 20% decrease themean QT value. The replicates where the test statistic is significant
were used for estimating genetic parameters for the variants with MAF% 1%. Mean values and standard deviations are shown for the
naive, BSS-corrected, and independent estimators, mean values are displayed as bar plots, and standard deviations are represented by
error bars. The true genetic variance and AGE-based genetic variance were calculated analytically. The reported values s2G and ðsCMCAGE Þ2
are averages over the replicates with significant test statistics. Examined scenarios included those in which (A) 10% of variants are causal
and ~bmax ¼ ~bmin ¼ 0:25, (B) 50% of variants are causal and ~bmax ¼ ~bmin ¼ 0:25, (C) 90% of variants are causal and ~bmax ¼ ~bmin ¼ 0:25, (D)
10% of variants are causal and ~bmax ¼ ~bmin ¼ 0:5, (E) 50% of variants are causal and ~bmax ¼ ~bmin ¼ 0:5, (F) 90% of variants are causal and
~bmax ¼ ~bmin ¼ 0:5, (G) 10% of variants are causal, ~bmax ¼ 0:75, and ~bmax ¼ 0:125, (H) 50% of variants are causal, ~bmax ¼ 0:75, and
~bmax ¼ 0:125, and (I) 90% of variants are causal, ~bmax ¼ 0:75, and ~bmax ¼ 0:125.We also compared the variances of different estimators.
In fact, the standard deviations for the BSS-corrected esti-
mators can be larger than those for the naive and indepen-
dent estimators. This is because the BSS-corrected esti-
mates are obtained from only a fraction of the sample
(i.e., the residual sample for each bootstrap). For instance,
in the analyses by CMC, when ~bs ¼ 0:5; s˛C and 50% of
the variants are causal, the standard deviation for the
BSS-corrected estimator is 0.145 3 102, which is slightly
larger than that of the naive estimator (0.132 3 102)
and the independent estimator (0.130 3 102) (Figure 1E).
Analysis of Sequence Data Set of ANGPTL3, ANGPTL4,
ANGPTL5, and ANGPTL6
Association testing was performed with the CMC and VT
methods. For each identified association, the naive and
corrected estimators for bAGE and s
2
AGE were reported. For592 The American Journal of Human Genetics 91, 585–596, Octoberthe analyses using the CMC and WSS methods, rare vari-
ants with MAF % 3% were grouped and jointly analyzed.
Two significant associations, i.e., the association between
ANGPTL4 and TG (p ¼ 0.002) and the association between
ANGPTL4 and VLDL (p ¼ 0.005), were identified by CMC
(Table 2). Only the association between ANGPTL4 and
TGwas identified byWSS (p¼ 0.038). Association analyses
were also performed with VT, where variants with
frequency % 5% were analyzed. Three associations, i.e.,
the associations between ANGPTL4 and TG (p ¼ 0.005
and MAF threshold ¼ 0.014), between ANGPTL4 and
VLDL (p ¼ 0.014 and MAF threshold ¼ 0.014), and
between ANGPTL5 and TCL (p ¼ 0.008 and MAF
threshold ¼ 0.031) were identified (Table 3).
We examined more closely the association between
ANGPTL5 and TCL; this association was only identified
by the VT test. One variant (c.803C>T [p.Thr268Met];5, 2012
Table 2. CMC and WSS Association Analyses for the ANGPTL3, ANGPTL4, ANGPTL5, and ANGPTL6 Sequence Data Set
Gene Trait p Value
Naive Estimates BSS-Corrected Estimates
bbnavieAGE ðbsnaiveAGE Þ2 bbBSSAGE ðbsBSSAGEÞ2
Analysis by CMC
ANGPTL4 TG 0.002 0.476 1.067 3 102 0.426 0.817 3 102
ANGPTL4 VLDL 0.005 0.436 0.893 3 102 0.375 0.687 3 102
Analysis by WSS
ANGPTL4 TG 0.038 0.493 0.486 3 102 0.356 0.196 3 102
Variants with MAFs % 3% were analyzed. For each nominally significant association, bAGE - and AGE-based genetic variance, s
2
AGE, was reported.RefSeq accession number NM_178127.4) in the region of
interest has an MAF of ~0.031 and thus was not included
in the analysis that used CMC and WSS. This variant on
its own is nominally significantly associated with TCL
(p ¼ 0.013). Therefore, when this potential causal variant
was excluded from the analysis because of the fixed MAF
cutoff that was applied, CMC and WSS failed to detect
the association signal.
For all the nominally significant associations, AGE and
AGE-based variance were estimated via both the naive
estimator and the BSS-corrected estimator. Concordant
with our simulation experiment, the BSS-corrected
estimator is usually smaller in scale, which indicates that
the naive estimator can be inflated as a result of the
winner’s curse. For some associations, the difference can
be fairly small. For example, for the association between
ANGPTL4 and TG, the estimated AGE and AGE-based
variances for the set of variants with MAF % 0.03 are,
respectively, (1) bbCMC;naiveAGE ¼ 0:476 and ðbsCMC;naiveAGE Þ2 ¼
1:0673102 and (2) bbCMC;BSSAGE ¼ 0:426 and ðbsCMC;BSSAGE Þ2 ¼
0:8173102. However, for some associations, the differ-
ence between the two estimators can be large. For ex-
ample, for the association between ANGPTL5 and
TCL, the naive estimators calculated for the group of
selected variants (i.e., variants with MAF % 0.031) are
bbVT ;naiveAGE ¼ 0:347 and ðbsVT ;naiveAGE Þ2 ¼ 0:7533102, whereas
the corrected estimators are bbVT ;BSSAGE ¼ 0:181 and
ðbsVT ;BSSAGE Þ2 ¼ 0:1113102.
The estimates of locus-specific genetic variances
obtained via WSS are smaller in scale than those obtainedTable 3. VT Association Analyses for the ANGPTL3, ANGPTL4, ANGPTL5
Gene Trait p Value
Naive Estimates
bbnavieAGE ðbsnaiveAGE Þ2
ANGPTL4 TG 0.005 0.476 1.067 3 1
ANGPTL4 VLDL 0.014 0.436 0.893 3 1
ANGPTL5 TCL 0.008 0.347 0.753 3 1
For each nominally significant association, the MAF threshold where the Z score sta
was reported for the set of variants determined by the optimal MAF threshold.
The Americvia CMC. Specifically, for the association between
ANGPTL4 and TG, the estimates are ðbsWSS;naiveAGE Þ2 ¼
0:4863102 and ðbsWSS;naiveAGE Þ2 ¼ 0:1963102, indicating
that the assigned weights are not optimal and might affect
the estimation of locus-specific genetic variance in aggre-
gate analysis.
For the association between TG and ANGPTL4 that was
replicated with an independent sample, the BSS-corrected
estimate for AGE-based genetic variance (i.e., ðbsCMC;BSSAGE Þ2)
is equal to 0.817 3 102. This suggests that rare variants
in ANGPTL4 explain at least ~0.8% of the overall pheno-
typic variance according to Equation 3. In a previous study,
the overall heritability of TG was estimated to be 0.49.35
Therefore, according to Equation 4, rare variants in
ANGPTL4 contribute R1.63% of the overall heritability
of TG.Discussion
In this article, the problem of estimating locus-specific
genetic effects and variances was investigated for
sequence-based genetic studies of rare variants. The results
have important implications for interpreting the identified
associations. For a given group of rare variants that are
jointly analyzed, we showed that it is possible to estimate
the AGE. The maximum-likelihood estimates or least-
square estimates are asymptotically consistent even if the
model used in the estimation differs from the true under-
lying genetic model. Estimates of the AGE can be affected
by the presence of noncausal variants and/or causal vari-
ants with effects of different directions or magnitudes., and ANGPTL6 Sequence Data Set
BSS-Corrected Estimates
MAF CutoffsbbBSSAGE ðbsBSSAGEÞ2
02 0.444 0.758 3 102 0.014
02 0.299 0.498 3 102 0.014
02 0.181 0.111 3 102 0.031
tistics are maximized is reported. bAGE - and AGE-based genetic variance, s
2
AGE,
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On the other hand, when multiple variants are jointly
analyzed, the AGE-based genetic variance defined in the
aggregate analysis is always no greater than the true
locus-specific genetic variance under a broad variety of
phenotypic models. Therefore, the locus-specific genetic
variance and the proportion of missing heritability ex-
plained by the gene locus will be underestimated.
The estimates of locus-specific genetic variance in aggre-
gate rare-variant association analysis will be affected by the
presence of noncausal variants and/or the presence of
causal variants with effects with different magnitudes or
directions. With an increasing proportion of noncausal
variants or a higher level of heterogeneities in the effects
of causal variants, the locus-specific genetic variance can
be underestimated to a greater extent. In addition, the esti-
mates of locus-specific genetic effects can also be affected
by the weights that are assigned to each variant site.
When suboptimal weights are used (e.g., the weights
used in Tang and Lin’s extension29), the estimated value
of s2AGE can be much lower than the true locus-specific
genetic variance and should be interpreted with caution.
When genetic model parameters are estimated from the
stage 1 sample where the association is identified, the esti-
mates can be inflated as a result of the winner’s curse. The
size of the bias due to the winner’s curse was investigated
for rare-variant association analysis. Compatible with ob-
servations in common-variant association analysis, the
magnitude of the bias is usually inversely correlated with
the power of the study. For some underpowered studies,
the bias can be considerably large. Inflated estimates of
genetic effects can lead to the underestimation of the size
of samples that are needed for follow-up studies and hence
the inability to replicate a genuine association. For associ-
ation analysis of common variants, it is usually possible to
obtain unbiased estimates of genetic parameters from a
stage 2 replication sample. However, for rare variants, there
is considerable heterogeneity of rare-variant sites and
frequencies even for closely related populations,19 which
affects the estimates of genetic effects. It is crucial to be
able to obtain unbiased estimates from the stage 1 study
where the association is identified. Through the BSS algo-
rithms that we developed, the bias due to the winner’s
curse can be consistently reduced even for studies with
very low power (~10%). The algorithm can be used with
all rare-variant tests that are based upon weighting or
collapsing rare variants or on variable selection techniques.
The Dallas Heart Study data set was analyzed with the
CMC, WSS, and VT tests. The identified associations coin-
cide with previously published results. The association
between ANGPTL4 and TG is mainly driven by the
p.GLU40LYS variant (c.118G>A; RefSeq accession number
NM_020581.2), which is relatively common within the
European population (the carrier frequency is ~3%). The
association between the c.118G>A variant in ANGPTL4
and TG was replicated in an independent data set. In our
analysis using VT, c.118G>Awas among the set of selected
rare variants for which the Z score statistics are maximized.594 The American Journal of Human Genetics 91, 585–596, OctoberThe estimate of bAGE for the set of selected variants is0.44
SD after correction, which is similar to the naive estimate.
For the analysis using WSS, the assigned weights are
inversely correlated to MAFs. Therefore, the c.118G>A
variant that is potentially causal was assigned a smaller
weight than other lower-frequency variants, which may
not be causal. Concordant with our simulation experi-
ment, it is clear that the locus-specific genetic variance
can be underestimated to a greater extent if the assigned
weights are not optimal. For the association between
ANGPTL5 and TCL, the BSS-corrected genetic effect esti-
mates are considerably smaller than the naive estimates.
This is an indication that the study might be underpow-
ered or that the identified signal might be a false-positive
result. Therefore, a replication study is needed to confirm
the identified association.36
Approaches based on the random-effects model can also
allow estimation of genetic effects or variance components.
However, given the complexity of the model, it is hard to
analytically explore the statistical properties of the esti-
mator under the alternative hypothesis. It was well known
that the inference can be biased if the assumptions of the
random-effects model are violated.37 Because of noncausal
variants or the fact that lower-frequency variants are more
likely to be functionally deleterious when effect sizes
are large,6 many key assumptions of the random-effects
model can be violated. It is therefore unclear how to
interpret the estimates obtained from these models.
The simulation experiments that are shown in this
article were limited to population-based random-sampling
designs. Because of the high sequencing cost, many studies
of complex traits have sequenced selected samples with
extreme traits. We have also simulated data sets for
extreme-sampling studies and examined the properties of
the AGE estimates. The results for the analysis using VT
and CMC remain unchanged, and the methods are also
applicable to extreme-sampling studies (data not shown).
For the analysis by WSS, the estimates have to be obtained
by least-square methods and therefore are not applicable
for studies where samples with extreme quantitative traits
are sequenced.
With the large-scale implementation of second-genera-
tion sequencing, the cost of generating and analyzing
sequence data is expected to drop rapidly. The scale
of sequence-based association studies will thus quickly
expand. In large-scale sequencing studies with thousands
of individuals, it is possible to analyze low-frequency vari-
ants (with MAF between 1% and 5%) or higher-frequency
rare variants (e.g., with MAF between 0.5% and 1%) indi-
vidually. In addition, with a large reference panel and
cohort of samples, some low-frequency variants can also
be accurately imputed from genotype data and analyzed
individually. However, as a result of purifying selections
and recent, rapid expansion of the human population,
there are numerous variant sites with very low fre-
quencies.18 As a larger number of samples are sequenced,
many more nucleotide sites with one or a few variants5, 2012
will be uncovered within a data set.26 In addition, some
identified associations are clearly driven by multiple vari-
ants with very low frequencies, such as singletons. Given
that the cumulative frequencies of these variants can be
sufficiently large for detecting associations, it is still neces-
sary and meaningful to aggregate rare variants in the gene
region and analyze them collectively. Therefore, the
methods introduced in this article will still be of great
importance for future large-scale sequencing studies.
As sequence sample size increases, loci with smaller
effect sizes can also be detected with high power. The
AGE values for these new loci are expected to be smaller.
For example, the identification of causal variants with
smaller effects or the presence of a greater portion of
noncausal variants in the genetic region can both lead to
the decrease of the magnitude of the AGE estimates.
When rare-variant association analysis shifts to the use of
whole-genome sequence data, the unit of analysis will
not be as clear as for exome sequencing (for which it is
usually a gene). Additionally, the annotation for non-
coding regions of the genome is not as straightforward as
for coding regions. The genetic locus can thus be contam-
inated with a higher proportion of noncausal variants. The
heritability that the genetic locus contributes can be
underestimated to a greater extent in aggregate analyses.
By reducing the discrepancy between AGE-based genetic
variance, s2AGE, and true locus-specific genetic variance, s
2
G,
the estimation for a gene region’s contribution to trait heri-
tability will be improved. It is clear from our proof in the
supplemental material that s2AGE and s
2
G are equivalent if
all variants in the genetic region have homogeneous effect
or when the optimal weights can be assigned. Therefore,
one possible future direction of research is to integrate
information from laboratory-based experiments or bio-
informatics so that noncausal and causal variants can be
more accurately distinguished and weighted or to use
variable-selection-based methods to select variants with
similar genetic effects. These new methods will be helpful
for improving the estimates of locus-specific genetic vari-
ance. However, as we proved theoretically, when multiple
rare variants are jointly analyzed, the locus-specific genetic
variance will always be underestimated. The bias cannot
be eliminated by any variable selection or weighting
methods, and the estimated value of s2AGE should be inter-
preted as a lower bound for the true locus-specific genetic
variance.
With growing application of next-generation sequenc-
ing, many rare-variant associations will be detected. These
findings need to be correctly interpreted. It is important to
be able to estimate relevant genetic parameters of interest
and quantify the proportion of heritability these novel
associations explain. However, when aggregate analysis is
performed for the detection of rare-variant associations,
the inclusion of noncausal variants or the presence of
causal variants with effects of different magnitudes or
directions might cause the heritability contributed by
rare variants to be underestimated.The AmericSupplemental Data
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